Intro:
-true oncological emergency❗️
-up to 6% of cancer patients
-annual incidence of hospitalizations secondary to MSCC among patients with advanced cancer ~3.5%
-multiple myeloma and non-Hodgkin lymphoma with highest cancer-specific incidence
-prognosis poor
2/11
Definition of MSCC:
-any radiologic evidence of indentation of the thecal sac or spinal cord compression, whether or not there are neurologic signs and symptoms associated with compression
-grading using the "epidural spinal cord compression (ESCC) scale" (Bilsky scale)
3/11
Pathophysiology:
-mostly due to metastases to vertebral bodies
👉erode into spinal canal & encroach on spinal cord
-paravertebral tumors can extend through neural foramina 👉cord compression
-intramedullary & meningeal rare
-Most locations: thoracic>lumbar>cervical spine
4/11
Clinic:
-back pain
-paralysis, sensory loss, bladder and bowel dysfunction can evolve rapidly
-Cauda equina syndrome👉compression in lumbosacral spine
-20% do not have a known cancer diagnosis at the time the MSCC is diagnosed❗️
-know your dermatomes❗️
5/11
Diagnosis:
-method of choice is MRI
-if possible, important to image ENTIRE spine because up to 40% have multiple levels of compression or cord impingement
-CT, with or without myelography, if MRI is contraindicated or not available
-assess ESCC and instability
6/11
Treatment:
-initiate without delay
-assess motor function before
-consider high-dose dexamethasone for severe deficits in whom small potential gain may outweigh the risks
-almost all patients should be evaluated urgently for a decompressive surgical procedure
8/11
Radiation:
-most patients, whether or not get decompressive surgery
-conventional external beam radiation therapy (cEBRT)
👉~70% pain improvement, 50% without instability with resolution
👉variety of schedules: single (8 Gy), protracted (30-40 Gy in 10-20 fractions)
9/11
Stereotactic body radiotherapy (SBRT):
-cEBRT limited by proximity of spinal cord
-SBRT with precisely targeted high dose to tumor (even separated by 2 to 3 millimeters from spinal cord)
BUT
-less useful for relatively radioresistant tumors
10/11
Summary for MSCC:
❗️Emergency
❗️Myeloma & non-Hodgkin lymphoma
❗️Thoracic>lumbar>cervical
❗️Pain, sensory & motor dysfunction, in ~40% first sign even before cancer diagnosis
❗️scales: ESCC & instability score
❗️MRI
❗️Treat immediately: dexamethasone, surgery +/- radiation
As a new medical student 10 years ago, I often asked myself:
What makes a good doctor and researcher?
After all these years, I’m amazed by how this still remains true in my heart today.
Here’s what I thought🧵
LEARN THE BASICS WELL
Medicine is like a building: your foundation matters. Don’t rush to memorize rare diseases before you’ve mastered anatomy, physiology, and pathology. Know your basics inside out.
BE CURIOUS, NOT JUST STUDIOUS
Don’t just learn for exams. Ask yourself:
Why does this happen?
How can I explain it to someone else?
Curiosity turns a good student into a lifelong learner.
Here's a thread on selected clinical studies we've seen this year🧵🩸
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia @NEJM
- asciminib showed superior efficacy and a favorable safety profile in patients with newly diagnosed chronic-phase CML
- BUT comparison with second-generation TKIs was not a primary objective!
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children @NEJM
- 3-year DFS was 96% with blinatumomab and chemotherapy and 88% with chemotherapy alone
- Cytokine release syndrome, seizures, and sepsis of grade 3 or higher were rare
Chimeric antigen receptor T cell therapy might revolutionize the management and our understanding of autoimmune diseases
An short educational thread🧵on current status and future directions
Intro:
- CAR T therapy was originally designed to fight cancer
- now showed transformative potential in treating autoimmune diseases by targeting B cells
👉key role in disease (progression)
- safety remains focus, with a milder toxicity profile emerging in autoimmune disease
B cells?
- arise in bone marrow and go to periphery
- differentiate into antibody-secreting plasma cell populations
👉short-lived plasmablasts + long-lived plasma cells
👉reside in bone marrow
- CD19, CD20, CD38, BCMA expressed at various stages
👉enable identification
The h-index is one of the most impactful and widely used metrics to assess a researcher’s productivity and citation impact.
How it started & how it's going
A thread🧵
History:
- 2005 by physicist Jorge E. Hirsch
- assess researcher’s productivity and citation impact
- argued that total citations are skewed by few highly cited papers
👉publication counts don’t account for influence of research
We will discuss later the "dilemma of quality"...
What's the h index?
- largest number h such that h articles have at least h citations each
👉if an author has 5 publications with 9, 7, 6, 2, 1 citations
👉h-index=3
👉3 publications with 3 or more citations
BUT
the author does not have 4 publications with >3 citations❗️
Elsevier is one of the largest, most hated and most influential academic publishing companies in the world.
How it started & how it's going
A thread🧵
Founding:
- 1580, family named Elzevir, led by Lodewijk Elzevir, founded original publishing house in Leiden🇳🇱
- family's printer's mark
👉tree entwined with a vine & the words Non Solus
👉Latin for "not alone"
👉symbiosis between publisher & scholar
We will see the irony later!
Early scoops:
- Elzevir was famed for its high-quality, small-format editions of scholarly works in 17th century
- famous publication of "Observationes Medicae", first illustration of chimpanzee
- notable other publications included works by Galileo Galilei and René Descartes
Today is World Chronic Myeloid Leukemia Day #WCMLD24
Time to educate, reflect and celebrate what has been achieved
A short educational thread on CML
Intro to CML:
-BCR-ABL1-positive
-classified as a myeloproliferative neoplasm
-predominantly composed of proliferating granulocytes and determined to have the Philadelphia chromosome/translocation t(9;22)(q34;q11.2)
-affects peripheral blood + bone marrow
Pathophysiology:
-fusion oncoprotein BCR-ABL1 defines CML
-90-95% have a shortened chromosome 22
👉reciprocal translocation t(9;22) (q34;q11.2)
👉Philadelphia chromosome
-oncoprotein acts as constitutively expressed defective tyrosine kinaseö